SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SPARC files draft paper to raise up to Rs 250 crore through rights issue

22 Sep 2015 Evaluate

Sun Pharma Advanced Research Company (SPARC) has filed draft papers with markets regulator Securities and Exchange Board of India (SEBI) to raise up to Rs 250 crore through a rights issue. Ernst & Young Merchant Banking Services, Inga Capital are the lead managers to the issue.

The company will issue equity shares aggregating up to Rs 25,000 lakh to its existing equity shareholders on a rights basis. The proceed of the issue will be utilized for meeting costs related to pharmaceutical research and development, clinical trials and for other general corporate purposes.

Sun Pharma Advanced Research Company is an international pharmaceutical company engaged in research and development of drugs and delivery systems.


Sun Pharma Adv. Res Share Price

250.25 -0.80 (-0.32%)
16-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Syngene Internatl. 419.35
Indegene 511.40
CMS Info Systems 268.45
JITF Infralogistics 359.65
Sagility 41.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: